Menu
D

DMI Research | Pinellas Park, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tofacitinib
Methotrexate
Desmopressin
Oseltamivir
CP-690,550
Bococizumab
Troriluzule
BMS-986177
CK-2017357
RN316

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Enrolling
Obsessive-Compulsive Disorder
Drug: Troriluzole
Drug: Placebo

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trial sponsors

Pfizer logo
Biohaven logo
Ferring logo
National Institute of Allergy and Infectious Diseases (NIAID) logo
AbbVie logo
Amgen logo
Bayer logo
BioCryst logo
Biogen logo
Cytokinetics logo